UPDATE 1-Biogen delays Alzheimer's drug filing plans, shares fall

Biogen Inc said on Wednesday it would delay filing for marketing approval of its much-awaited experimental Alzheimer's disease drug to the third quarter, sending its shares down 7%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.